Artigo
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET
Autor(es): A. Gennari, E. Brain, A. De Censi, O. Nanni, R. Wuerstlein, A. Frassoldati, J. Cortes, V. Rossi, M. Palleschi, J.L. Alberini, F. Matteucci, A. Piccardo, G. Sacchetti, H. Ilhan, F. D’Avanzo, B. Ruffilli, S. Nardin, M. Monti, M. Puntoni, V. Fontana, L. Boni, N. Harbeck, on behalf of the ET-FES Collaborative Group
ABSTRACT
– 18F-FES PET/CT may be used as a predictive tool of efficacy of ET to assess overall
endocrine sensitivity.
– Endocrine sensitive patients (SUVmax≥2) treated with single agent ET have a prolonged
overall survival.
– In endocrine sensitive patients PFS and OS related to the use of AI was significantly higher
than ER directed agents.
– 18F-FES PET/CT can be used as a valid alternative to biopsy.
Compartilhar em:
Comentários
Cursos Relacionados
7 Aulas
7 Horas
R$249 a R$399
0
Conteúdos Relacionados
16:37
Mastologia
25/06/2024
17:55
01:21:57
54:55
08:49
Comentários
Deixe um comentário
Você precisa fazer o login para publicar um comentário.
